Mucosal Permeability and Immune Activation as Potential Therapeutic Targets of Probiotics in Irritable Bowel Syndrome

被引:75
|
作者
Barbara, Giovanni
Zecchi, Lisa
Barbaro, Raffaella
Cremon, Cesare
Bellacosa, Lara
Marcellini, Marco
De Giorgio, Roberto
Corinaldesi, Roberto
Stanghellini, Vincenzo
机构
[1] Univ Bologna, Dept Clin Med, I-40138 Bologna, Italy
[2] Univ Bologna, Ctr Appl Biomed Res, I-40138 Bologna, Italy
关键词
irritable bowel syndrome; mast cells; abdominal pain; mucosal barrier; immune activation; RANDOMIZED CONTROLLED-TRIAL; DIARRHEA-PREDOMINANT IBS; CROSS-OVER TRIAL; DOUBLE-BLIND; MAST-CELLS; INTESTINAL PERMEABILITY; FECAL MICROBIOTA; BARRIER FUNCTION; SYMPTOMS; EFFICACY;
D O I
10.1097/MCG.0b013e318264e918
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
There is increasingly convincing evidence supporting the participation of the gut microenvironment in the pathophysiology of irritable bowel syndrome (IBS). Studies particularly suggest an interplay between luminal factors (eg, foods and bacteria residing in the intestine), the epithelial barrier, and the mucosal immune system. Decreased expression and structural rearrangement of tight junction proteins in the small bowel and colon leading to increased intestinal permeability have been observed, particularly in post-infectious IBS and in IBS with diarrhea. These abnormalities are thought to contribute to the outflow of antigens through the leaky epithelium, causing overstimulation of the mucosal immune system. Accordingly, subsets of patients with IBS show higher numbers and an increased activation of mucosal immunocytes, particularly mast cells. Immune factors, released by these cells, including proteases, histamine, and prostanoids, participate in the perpetuation of the permeability dysfunction and contribute to the activation of abnormal neural responses involved in abdominal pain perception and changes in bowel habits. All these mechanisms represent new targets for therapeutic approaches in IBS. Probiotics are an attractive therapeutic option in IBS given their recognized safety and by virtue of positive biological effects they can exert on the host. Of importance for the IBS pathophysiology is that preclinical studies have shown that selective probiotic strains exhibit potentially useful properties including anti-inflammatory effects, improvement of mucosal barrier homeostasis, beneficial effects on intestinal microbiota, and a reduction of visceral hypersensitivity. The effect of probiotics on IBS is positive in most randomized, controlled studies, although the gain over the placebo is small. Identifying tailored probiotic approaches for subgroups of IBS patients represents a challenge for the future.
引用
收藏
页码:S52 / S55
页数:4
相关论文
共 50 条
  • [1] Potential neuro-immune therapeutic targets in irritable bowel syndrome
    Casado-Bedmar, Maite
    Keita, Asa, V
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2020, 13
  • [2] Activation of the mucosal immune system in irritable bowel syndrome
    Chadwick, VS
    Chen, WX
    Shu, DR
    Paulus, B
    Bethwaite, P
    Tie, A
    Wilson, I
    GASTROENTEROLOGY, 2002, 122 (07) : 1778 - 1783
  • [3] Probiotics as therapeutic agents in irritable bowel syndrome
    Krammer, HJ
    Schlieger, F
    Harder, H
    Franke, A
    Singer, MV
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2005, 43 (05): : 467 - 471
  • [4] Probiotics in Irritable Bowel Syndrome: A Review of Their Therapeutic Role
    Kumar, Lakshmi Satish
    Pugalenthi, Lakshmi Sree
    Ahmad, Mahlika
    Reddy, Sanjana
    Barkhane, Zineb
    Elmadi, Jalal
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (04)
  • [5] Irritable Bowel Syndrome and Immune Activation
    Choi, Chang Hwan
    Sul, Hye Ryoung
    INTESTINAL RESEARCH, 2008, 6 (02) : 95 - 102
  • [6] Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome
    Jovani, M.
    Fiorino, G.
    Danese, S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (02) : 277 - 278
  • [7] Mucosal Immune Biomarkers in Patients With Irritable Bowel Syndrome
    Cremon, Cesare
    Zecchi, Lisa
    Barbaro, Raffaella M.
    Lateana, Antonella M.
    Fiorentino, Michelangelo
    Altimari, Annalisa
    Carini, Giovanni
    De Giorgio, Roberto
    Corinaldesi, Roberto
    Stanghellini, Vincenzo
    Barbara, Giovanni
    GASTROENTEROLOGY, 2013, 144 (05) : S150 - S150
  • [8] Protease-activated receptors: potential therapeutic targets in irritable bowel syndrome?
    Gloro, R
    Ducrotte, P
    Reimund, JM
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2005, 9 (05) : 1079 - 1095
  • [9] Probiotics and irritable bowel syndrome
    Dai, Cong
    Zheng, Chang-Qing
    Jiang, Min
    Ma, Xiao-Yu
    Jiang, Li-Juan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (36) : 5973 - 5980
  • [10] Probiotics and irritable bowel syndrome
    Camilleri, Michael
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2008, 42 (08) : S123 - S125